KR20240165959A - 안면견갑상완 근이영양증(fshd)의 새로운 치료법 - Google Patents

안면견갑상완 근이영양증(fshd)의 새로운 치료법 Download PDF

Info

Publication number
KR20240165959A
KR20240165959A KR1020247032600A KR20247032600A KR20240165959A KR 20240165959 A KR20240165959 A KR 20240165959A KR 1020247032600 A KR1020247032600 A KR 1020247032600A KR 20247032600 A KR20247032600 A KR 20247032600A KR 20240165959 A KR20240165959 A KR 20240165959A
Authority
KR
South Korea
Prior art keywords
myostatin
antibody
seq
set forth
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247032600A
Other languages
English (en)
Korean (ko)
Inventor
엘레니 가키
태미 맥이버
스칼코 레나타 시칠리아니
캐서린 래 바그너
와이 인 영
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20240165959A publication Critical patent/KR20240165959A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020247032600A 2022-04-01 2023-03-30 안면견갑상완 근이영양증(fshd)의 새로운 치료법 Pending KR20240165959A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22166261 2022-04-01
EP22166261.2 2022-04-01
PCT/EP2023/058218 WO2023187022A1 (en) 2022-04-01 2023-03-30 New treatment for facioscapulohumeral muscular dystrophy (fshd)

Publications (1)

Publication Number Publication Date
KR20240165959A true KR20240165959A (ko) 2024-11-25

Family

ID=81328333

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247032600A Pending KR20240165959A (ko) 2022-04-01 2023-03-30 안면견갑상완 근이영양증(fshd)의 새로운 치료법

Country Status (11)

Country Link
US (1) US20250171526A1 (https=)
EP (1) EP4504779A1 (https=)
JP (1) JP2025511167A (https=)
KR (1) KR20240165959A (https=)
CN (1) CN119053619A (https=)
AU (1) AU2023246859A1 (https=)
CA (1) CA3255735A1 (https=)
IL (1) IL315473A (https=)
MX (1) MX2024011922A (https=)
TW (1) TW202346345A (https=)
WO (1) WO2023187022A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
AR107078A1 (es) 2015-12-18 2018-03-21 Chugai Pharmaceutical Co Ltd Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso

Also Published As

Publication number Publication date
AU2023246859A1 (en) 2024-09-05
TW202346345A (zh) 2023-12-01
AU2023246859A9 (en) 2024-09-12
EP4504779A1 (en) 2025-02-12
JP2025511167A (ja) 2025-04-15
MX2024011922A (es) 2024-11-08
WO2023187022A1 (en) 2023-10-05
IL315473A (en) 2024-11-01
CN119053619A (zh) 2024-11-29
CA3255735A1 (en) 2023-10-05
US20250171526A1 (en) 2025-05-29

Similar Documents

Publication Publication Date Title
AU2020210134B2 (en) Use of myostatin inhibitors and combination therapies
JP7426369B2 (ja) 遺伝性血管性浮腫の発作を治療するための血漿カリクレイン阻害薬およびその用途
JP6845012B2 (ja) 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用
US20230365669A1 (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
PT2625199T (pt) Métodos de tratamento de psoríase usando antagonistas de il-17
TW201536318A (zh) 治療偶發性包涵體肌炎之方法
TW201622746A (zh) 改善或加速髖部骨折術後身體復原之方法
JP7585193B2 (ja) 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用
US20240358704A1 (en) Combined administration
KR20220054608A (ko) ActRII 수용체 길항제를 포함하는 간 질환 또는 장애 치료제
US10961305B2 (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
AU2018361975A1 (en) Method of treating tendinopathy using interleukin-17 (IL-17) antagonists
KR20190090820A (ko) 오피오이드 중독 방지를 위한 약학 조성물
KR20240165959A (ko) 안면견갑상완 근이영양증(fshd)의 새로운 치료법
HK40112393A (zh) 用於面肩肱型肌营养不良症(fshd)的新治疗
HK40103690A (zh) 新颖的组合施用
KR20250011951A (ko) 인터루킨-17 (il-17) 길항제를 사용한 거대 세포 동맥염의 치료 방법
EA045920B1 (ru) Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240930

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application